What is the mainstay intervention to improve progressive shortness of breath in COPD patients with FEV1 >50% and no frequent exacerbations who are already on LABA and SABA PRN?

What is the mainstay intervention to improve progressive shortness of breath in COPD patients with FEV1 >50% and no frequent exacerbations who are already on LABA and SABA PRN?

• A. Oxygen therapy
• B. Pulmonary rehabilitation
• C. Increase inhaled corticosteroids
• D. Lung transplant

Answer: (B)

Pulmonary rehabilitation is the most effective approach to address progressive breathlessness and limited exercise tolerance in COPD when FEV1 is above 50% and exacerbation risk is not high. It combines supervised aerobic and resistance training, education, breathing techniques, and energy-conservation strategies. This program consistently improves dyspnea, increases exercise capacity, enhances quality of life, and can reduce hospitalizations, making it the best next step for a patient already on a LABA and PRN SABA. Oxygen therapy is reserved for patients with chronic hypoxemia and is not indicated solely for dyspnea. Increasing inhaled corticosteroids is not the primary fix for dyspnea in a patient without frequent exacerbations, and lung transplantation is only for end-stage disease with refractory symptoms despite maximal therapy.

Pulmonary rehabilitation is the most effective approach to address progressive breathlessness and limited exercise tolerance in COPD when FEV1 is above 50% and exacerbation risk is not high. It combines supervised aerobic and resistance training, education, breathing techniques, and energy-conservation strategies. This program consistently improves dyspnea, increases exercise capacity, enhances quality of life, and can reduce hospitalizations, making it the best next step for a patient already on a LABA and PRN SABA.

Oxygen therapy is reserved for patients with chronic hypoxemia and is not indicated solely for dyspnea. Increasing inhaled corticosteroids is not the primary fix for dyspnea in a patient without frequent exacerbations, and lung transplantation is only for end-stage disease with refractory symptoms despite maximal therapy.